BCLI News and Press, Brainstorm Cell Therapeutics Inc. From 06/20/23

BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair PR Newswire NEW YORK , June 20, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegen...

BrainStorm Cell Therapeutics to Participate in the Maxim Group Healthcare Virtual Conference PR Newswire NEW YORK , June 16, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurod...

2023-06-09 16:39:45 ET Summary Brainstorm Cell Therapeutics faces uncertainty in the approval process for its NurOwn treatment for neurodegenerative diseases, with a pivotal ADCOM meeting scheduled for September 27, 2023. The company's corrected data from Phase 3 trials show promi...

2023-06-06 15:05:56 ET BrainStorm Cell Therapeutics ( NASDAQ: BCLI ) said that a US Food and Drug Administration advisory committee is set to review its biologics license application on Sept. 27 for its stem cell therapy NurOwn for the treatment of amyotrophic lateral sclerosis, or ...

BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review NurOwn® Biologics License Application Scheduled for September 27, 2023 PR Newswire PDUFA target action date set to occur by December 8, 2023 NEW YORK , June 6, 2023 /...

2023-05-24 17:55:20 ET Brainstorm Cell Therapeutics ( NASDAQ: BCLI ) disclosed in an SEC filing Wednesday that David Setboun will resign as EVP and COO of the company, effective May 31. SEC filing . For further details see: Brainstorm Cell COO Setboun to ...

BrainStorm Cell Therapeutics Summarizes Key Messages from Its Participation as Expert Speakers in an Invited Presentation and Panel Discussion at The 2023 ALS Drug Development Summit PR Newswire - Presentation by Co-CEO Stacy Lindborg , Ph.D., held at 2023 ALS Drug Develop...

2023-05-15 10:27:07 ET Brainstorm Cell Therapeutics Inc. (BCLI) Q1 2023 Earnings Conference Call May 15, 2023, 08:00 AM ET Company Participants Michael Wood - LifeSci Advisors Chaim Lebovits - President and CEO Stacy Lindborg - Co-CEO Alla Patlis - Interim CF...

2023-05-15 07:13:08 ET BrainStorm Cell Therapeutics press release ( NASDAQ: BCLI ): Q1 GAAP EPS of -$0.14 beats by $0.03 . Cash, cash equivalents, and short-term bank deposits were approximately $2.2M as of March 31, 2023, compared to $3 million as of December 31, 2022...

BrainStorm Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Biologics License Application for NurOwn® for the treatment of ALS to be subject of an upcoming FDA Advisory Committee Meeting Conference call and webca...